

Marcell Csányi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5135973/publications.pdf>

Version: 2024-02-01

44
papers

745
citations

687363

13
h-index

610901

24
g-index

45
all docs

45
docs citations

45
times ranked

990
citing authors

#	ARTICLE	IF	CITATIONS
1	Burden of Chronic Heart Failure in Romania. <i>Healthcare (Switzerland)</i> , 2022, 10, 107.	2.0	6
2	Secondary primary malignancies after treatment with chemo-immunotherapy in treatment-naïve patients with CLL: a systematic literature review. <i>Expert Review of Hematology</i> , 2022, 15, 273-284.	2.2	2
3	Pricing strategies, executive committee power and negotiation leverage in New Zealand's containment of public spending on pharmaceuticals. <i>Health Economics, Policy and Law</i> , 2022, 17, 348-365.	1.8	3
4	A "patient" industry complex? Investigating the financial dependency of UK patient organisations on drug company funding. <i>Sociology of Health and Illness</i> , 2022, 44, 188-210.	2.1	7
5	Modeling costs and benefits of the organized colorectal cancer screening programme and its potential future improvements in Hungary. <i>Journal of Medical Screening</i> , 2021, 28, 268-276.	2.3	11
6	The EU-TOPIA evaluation tool: An online modelling-based tool for informing breast, cervical, and colorectal cancer screening decisions in Europe. <i>Preventive Medicine Reports</i> , 2021, 22, 101392.	1.8	7
7	Early palliative care associated with lower costs for adults with advanced cancer: evidence from Hungary. <i>European Journal of Cancer Care</i> , 2021, 30, e13473.	1.5	2
8	Development and Validation of Three Regional Microsimulation Models for Predicting Colorectal Cancer Screening Benefits in Europe. <i>MDM Policy and Practice</i> , 2021, 6, 238146832098497.	0.9	4
9	The Emerging Social Science Literature on Health Technology Assessment: A Narrative Review. <i>Value in Health</i> , 2020, 23, 3-9.	0.3	14
10	The influence of health systems on breast, cervical and colorectal cancer screening: an overview of systematic reviews using health systems and implementation research frameworks. <i>Journal of Health Services Research and Policy</i> , 2020, 25, 49-58.	1.7	16
11	Influence of biosimilar infliximab launch on the utilization pattern of biological medicines: the case of Hungary. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 653-659.	1.4	8
12	Current and future perspectives for the implementation of health technology assessment in Romania. <i>Health Policy and Technology</i> , 2020, 9, 45-52.	2.5	8
13	Patient-reported symptom burden of chronic graft versus host disease: a systematic literature review. <i>Expert Review of Hematology</i> , 2020, 13, 1119-1130.	2.2	1
14	Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012-2016). <i>BMJ Open</i> , 2020, 10, e037351.	1.9	14
15	Cost Assessment of Inpatient Care Episodes of Stroke in Romania. <i>Frontiers in Public Health</i> , 2020, 8, 605919.	2.7	8
16	Impact of colorectal cancer screening on cancer-specific mortality in Europe: A systematic review. <i>European Journal of Cancer</i> , 2020, 127, 224-235.	2.8	101
17	Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review. <i>European Journal of Cancer</i> , 2020, 127, 207-223.	2.8	120
18	Implementation of palliative care consult Service in Hungary - integration barriers and facilitators. <i>BMC Palliative Care</i> , 2020, 19, 41.	1.8	11

#	ARTICLE	IF	CITATIONS
19	Development of transferability guidance for integrated care models with special focus on Central and Eastern European countries. Croatian Medical Journal, 2020, 61, 252-259.	0.7	5
20	All-cause mortality versus cancer-specific mortality as outcome in cancer screening trials: A review and modeling study. Cancer Medicine, 2019, 8, 6127-6138.	2.8	27
21	Analysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015. JAMA Network Open, 2019, 2, e196253.	5.9	37
22	Is there a fair allocation of healthcare research funds by the European Union?. PLoS ONE, 2019, 14, e0207046.	2.5	8
23	Health Technology Assessment Implementation in Ukraine: Current Status and Future Perspectives. International Journal of Technology Assessment in Health Care, 2019, 35, 393-400.	0.5	7
24	Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology. Health Policy, 2019, 123, 630-634.	3.0	9
25	Patterns of alternative access: Unpacking the Slovak extraordinary drug reimbursement regime 2012-2016. Health Policy, 2019, 123, 713-720.	3.0	7
26	Planning, implementation and operation of a personalized patient management system for subjects with first suspect of cancer (OnkoNetwork): system description based on a qualitative study. BMC Health Services Research, 2019, 19, 131.	2.2	10
27	A systematic literature review of incidence, mortality, and relapse of patients diagnosed with chronic graft versus host disease. Expert Review of Hematology, 2019, 12, 311-323.	2.2	18
28	Humanistic burden of patients with chronic graft-versus-host disease - systematic literature review of health-related quality of life and functional status. Expert Review of Hematology, 2019, 12, 295-309.	2.2	11
29	Shedding light on the HTA consultancy market: Insights from Poland. Health Policy, 2019, 123, 1237-1243.	3.0	4
30	<p>Benefits Of Timely Care In Pancreatic Cancer: A Systematic Review To Navigate Through The Contradictory Evidence</p>. Cancer Management and Research, 2019, Volume 11, 9849-9861.	1.9	19
31	Key indicators of organized cancer screening programs: Results from a Delphi study. Journal of Medical Screening, 2019, 26, 120-126.	2.3	10
32	A choice experiment to identify the most important elements of a successful cancer screening program according to those who research and manage such programs. International Journal of Health Planning and Management, 2019, 34, e34-e45.	1.7	3
33	When health technology assessment is confidential and experts have no power: the case of Hungary. Health Economics, Policy and Law, 2019, 14, 162-181.	1.8	18
34	Transparency in practice: Evidence from â€˜verification analysesâ€™ issued by the Polish Agency for Health Technology Assessment in 2012â€“2015. Health Economics, Policy and Law, 2019, 14, 182-204.	1.8	9
35	Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure and Iron Deficiency in Romania. Journal of Cardiovascular Emergencies, 2019, 5, 131-139.	0.2	6
36	Clinical impact of treatment delay in pancreatic cancer patients revisited. International Journal of Cancer, 2018, 142, 2621-2622.	5.1	6

#	ARTICLE	IF	CITATIONS
37	Results of a health systems approach to identify barriers to population-based cervical and colorectal cancer screening programmes in six European countries. <i>Health Policy</i> , 2018, 122, 1206-1211.	3.0	11
38	Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts. <i>BioMed Research International</i> , 2018, 2018, 1-9.	1.9	23
39	The implications of external price referencing on pharmaceutical list prices in Europe. <i>Health Policy and Technology</i> , 2018, 7, 243-250.	2.5	13
40	OVERVIEW ON THE CURRENT IMPLEMENTATION OF HEALTH TECHNOLOGY ASSESSMENT IN THE HEALTHCARE SYSTEM IN HUNGARY. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 333-338.	0.5	8
41	HTA Implementation in Latin American Countries: Comparison of Current and Preferred Status. <i>Value in Health Regional Issues</i> , 2017, 14, 20-27.	1.2	19
42	Drug Policy in Hungary. <i>Value in Health Regional Issues</i> , 2017, 13, 16-22.	1.2	14
43	Is there a reason for concern or is it just hype? â€œ A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 915-926.	3.1	38
44	HTA Implementation Roadmap in Central and Eastern European Countries. <i>Health Economics (United Kingdom)</i> , 2017, 37, 1071-1082.	1.7	62